M&A Deal Summary |
|
|---|---|
| Date | 2009-11-05 |
| Target | Swedish Orphan International |
| Sector | Healthcare Services |
| Buyer(s) | SOBI |
| Sellers(s) | Priveq |
| Deal Type | Add-on Acquisition |
| Deal Value | 3.5B SEK |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1939 |
| Sector | Life Science |
| Employees | 1,772 |
| Revenue | 22.1B SEK (2023) |
SOBI is an integrated biopharmaceutical company with an international market presence, developing and commercializing pharmaceuticals for patients with rare diseases. SOBI was founded in 1939 and is headquartered in Solna, Sweden.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 4 |
| Sector (Healthcare Services) | 1 of 1 |
| Type (Add-on Acquisition) | 2 of 4 |
| Country (Sweden) | 1 of 1 |
| Year (2009) | 1 of 1 |
| Size (of disclosed) | 3 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-03-21 |
Cambridge Biotechnology
Cambridge, United Kingdom Cambridge Biotechnology Ltd. is a Cambridge UK based private drug discovery company. CBT's drug discovery efforts have been focused on obesity, pain and inflammation, utilizing the company's top class scientific and technical skills in the field of cytokine receptors. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-09-30 |
Dova Pharmaceuticals
Durham, North Carolina, United States Dova Pharmaceuticals, Inc. is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet medical need. Dova Pharmaceuticals was founded in 2016 and is headquartered in Durham, North Carolina. |
Buy | $915M |
| Category | Private Equity Firm |
|---|---|
| Founded | 1983 |
| PE ASSETS | 6.3B SEK |
| Size | Middle-Market |
| Type | Sector Agnostic |
Priveq is a private equity firm that invests in privately owned, small and medium-sized Scandinavian companies. Priveq targets profitable businesses with strong market positions and growth potential. The Firm looks to invest SEK 5 – 200 million in companies with sales typically greater than SEK 100 million. Priveq generally seeks equity between 30 and 70 percent in portfolio companies. The Firm will invest in a wide range of industries, but avoids real estate. Prospective transaction types include MBOs and growth capital financings. Priveq Investment was formerly known as Skandia Investment AB. The Firm was formed in 1983 and is based in Stockholm.
| DEAL STATS | # |
|---|---|
| Overall | 6 of 34 |
| Sector (Healthcare Services) | 2 of 4 |
| Type (Add-on Acquisition) | 3 of 12 |
| Country (Sweden) | 6 of 31 |
| Year (2009) | 1 of 1 |
| Size (of disclosed) | 1 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-05-07 |
Carmel Pharma AB
Molndal, Sweden Carmel Pharma ab engages in the manufacture and distribution of products that improve the quality of life of people who prepare, administer, and dispose of hazardous drugs. It offers the PhaSeal System, a closed-system drug transfer device that prevents hazardous drug interaction with the environment. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-11-09 |
Vårdapoteket i Norden AB
Malmo, Sweden As part of the Swedish Government sell-off of its former pharmacy monopoly, Priveq Investment and Investor Growth Capital are acquiring the pharmacies in clusters 6 and 7 offered by Apoteket Omstrukturering AB through newly incorporated entity Vårdapoteket i Norden AB. The operation consists of 24 outpatient dispensing pharmacies located on-site in hospitals, concentrated in central and southern Sweden. Vårdapoteket i Norden AB will have sales of over SEK 1,400 m and some 250 employees with solid pharmaceutical skills and backgrounds. |
Buy | - |
